Top Clinical Trials companies in Japan by Current Liabilities
Japan
# |
Name |
Current Liabilities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 15.28 B
|
March 31, 2024 | USD 27.12 | 0.10% |
|
Japan |
|
| 2 |
USD 8.49 B
|
March 31, 2024 | USD 9.76 | -1.53% |
|
Japan |
|
| 3 |
USD 2.04 B
|
Dec. 31, 2023 | USD 43.39 | 5.16% |
|
Japan |
|
| 4 |
USD 944.25 M
|
Dec. 31, 2023 | USD 14.95 | -1.71% |
|
Japan |
|
| 5 |
USD 884.72 M
|
March 31, 2024 | USD 14.75 | -0.46% |
|
Japan |
|
| 6 |
USD 613.10 M
|
March 31, 2024 | USD 10.09 | 0.15% |
|
Japan |
|
| 7 |
USD 300.56 M
|
March 31, 2024 | USD 9.48 | -0.72% |
|
Japan |
|
| 8 |
USD 256.50 M
|
March 31, 2024 | USD 9.47 | -2.44% |
|
Japan |
|
| 9 |
USD 249.04 M
|
Sept. 30, 2024 | USD 9.46 | -2.05% |
|
Japan |
|
| 10 |
USD 199.10 M
|
March 31, 2024 | USD 3.56 | -3.55% |
|
Japan |
|
| 11 |
USD 155.71 M
|
March 31, 2024 | USD 10.95 | -0.53% |
|
Japan |
|
| 12 |
USD 121.79 M
|
Dec. 31, 2023 | USD 6.24 | -4.05% |
|
Japan |
|
| 13 |
USD 116.70 M
|
March 31, 2024 | USD 25.51 | -0.96% |
|
Japan |
|
| 14 |
USD 82.69 M
|
March 31, 2024 | USD 17.95 | -0.66% |
|
Japan |
|
| 15 |
USD 66.55 M
|
June 30, 2024 | USD 8.09 | -0.35% |
|
Japan |
|
| 16 |
USD 61.07 M
|
Dec. 31, 2023 | USD 13.83 | -0.63% |
|
Japan |
|
| 17 |
USD 55.23 M
|
Dec. 31, 2023 | USD 21.58 | 0.31% |
|
Japan |
|
| 18 |
USD 51.33 M
|
March 31, 2024 | USD 2.22 | 6.19% |
|
Japan |
|
| 19 |
USD 51.30 M
|
March 31, 2024 | USD 15.32 | -0.42% |
|
Japan |
|
| 20 |
USD 47.20 M
|
March 31, 2024 | USD 11.15 | -1.27% |
|
Japan |
|
| 21 |
USD 6.16 M
|
Jan. 31, 2024 | USD 4.64 | 0.11% |
|
Japan |
|
| 22 |
USD 4.48 M
|
March 31, 2024 | USD 0.72 | 0.32% |
|
Japan |
|
| 23 |
USD 4.24 M
|
June 30, 2024 | USD 1.03 | -3.60% |
|
Japan |
|
| 24 |
USD 3.54 M
|
March 31, 2024 | USD 5.69 | -0.47% |
|
Japan |
|
| 25 |
USD 3.21 M
|
March 31, 2024 | USD 0.90 | -0.59% |
|
Japan |
|
| 26 |
USD 2.78 M
|
March 31, 2024 | USD 2.10 | -1.79% |
|
Japan |
|
| 27 |
USD 2.76 M
|
Dec. 31, 2023 | USD 2.56 | -2.54% |
|
Japan |
|
| 28 |
USD 2.68 M
|
Dec. 31, 2023 | USD 3.68 | -3.46% |
|
Japan |
|
| 29 |
USD 2.66 M
|
Dec. 31, 2023 | USD 1.90 | -2.24% |
|
Japan |
|
| 30 |
USD 2.38 M
|
March 31, 2024 | USD 0.17 | -10.87% |
|
Japan |
|
| 31 |
USD 2.08 M
|
Dec. 31, 2023 | USD 0.24 | -0.59% |
|
Japan |
Frequently Asked Questions
-
Which Clinical Trials company in Japan has the highest Current Liabilities ?
The Clinical Trials company in Japan with the highest Current Liabilities is Takeda Pharmaceutical Company Limited (Tokyo Stock Exchange: 4502.T) at USD 15.28 B.
-
Which Clinical Trials company in Japan has the lowest Current Liabilities ?
The Clinical Trials company in Japan with the lowest Current Liabilities is Solasia Pharma K.K. (Tokyo Stock Exchange: 4597.T) at USD 2.08 M.
-
What are the top 10 Clinical Trials companies in Japan by Current Liabilities ?
The top 10 Clinical Trials companies in Japan by Current Liabilities are Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Shionogi & Co., Ltd., Santen Pharmaceutical Co., Ltd., KYORIN Holdings, Inc., Qol Holdings Co., Ltd., Fuji Pharma Co., Ltd. and JCR Pharmaceuticals Co., Ltd..
-
What are the bottom 10 Clinical Trials companies in Japan by Current Liabilities ?
The bottom 10 Clinical Trials companies in Japan by Current Liabilities are Solasia Pharma K.K., OncoTherapy Science, Inc., Carna Biosciences, Inc., Oncolys BioPharma Inc., RaQualia Pharma Inc., PhoenixBio Co., Ltd., NanoCarrier Co., Ltd., Cytori Cell Research Institute, Inc., Soiken Holdings Inc. and ReproCELL Incorporated.
